Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine, S-1, and sorafenib for inoperable hilar cholangiocarcinoma
ChiCTR-TRC-14004737Phase 4Completed
- Sponsor
- Shanghai Sixth People's Hospital
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of gemcitabine, tegafur and sorafenib in hilar cholangiocarcinoma (HC) (3 arms), sponsored by Shanghai Sixth People's Hospital. Primary endpoint: Leukocytes. Started Jun 2014; status: completed.
02
Drugs
gemcitabinetegafursorafenib
03
Conditions
hilar cholangiocarcinoma (HC)
Beyond the preview
Go deeper on ChiCTR-TRC-14004737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-14004737.